论文部分内容阅读
目的检测急性白血病(AL)患者血浆中可溶性尿激酶型纤溶酶原激活剂受体(suPAR)的水平。方法采用酶联免疫吸附测定(ELISA)法检测53例AL血浆suPAR,并与20名正常人进行对照。结果急性非淋巴细胞性白血病(ANLL)、急性淋巴细胞性白血病(ALL)患者血浆suPAR高于正常对照组,差异有统计学意义(t值分别为7.71,7.08,P<0.01)。41例ANLL患者血浆suPAR水平与外周血白血病细胞数成正相关(r=0.494,P<0.05)。血浆suPAR水平明显升高组较非明显升高组髓外浸润发生率高,完全缓解率低(χ2=4.471,4.911,P<0.05)。完全缓解后ANLL血浆suPAR水平较治疗前明显下降(t=3.304,P<0.01)。结论检测血浆suPAR水平有助于判断AL患者疾病状态、评估预后。
Objective To detect the plasma levels of soluble uPAR in patients with acute leukemia (AL). Methods 53 cases of AL plasma suPAR were detected by enzyme linked immunosorbent assay (ELISA) and compared with 20 normal subjects. Results The plasma levels of suPAR in acute non-lymphocytic leukemia (ANLL) and acute lymphoblastic leukemia (ALL) patients were significantly higher than those in normal controls (t = 7.71, 7.08, P <0.01). The plasma level of suPAR in 41 patients with ANLL was positively correlated with the number of peripheral leukemia cells (r = 0.494, P <0.05). The incidence of extramedullary infiltration was significantly higher in patients with significantly higher plasma suPAR levels than in patients without obvious elevation (χ2 = 4.471, 4.911, P <0.05). After complete remission ANLL plasma suPAR levels were significantly lower than before treatment (t = 3.304, P <0.01). Conclusion The detection of plasma suPAR level is helpful to judge the disease status of AL patients and evaluate the prognosis.